Investment Insights from NewRetro Bio's Nearly RMB 100 Million Financing: The Investment Value of In Situ Transdifferentiation Technology

May 21, 2026 07:11 CST Updated 07:11

NEUREGEN

Novel Gene Therapy Drug Developer

On May 20, a major financing deal in the biopharmaceutical field was finalized: NEUREGEN, a leading company in in-situ transdifferentiation technology, announced the completion of its Series A financing round. The round was led by Wuhan Optics Valley Sci-Tech Industry Investment Fund, with Zhuhai Hengqin SoftBank Xinchuang following up, and existing shareholders continuing to increase their investment. Together with the previous Pre-A+ round, the company has cumulatively raised nearly 100 million yuan within a year, injecting momentum into the clinical advancement of core pipelines and technological iteration.

The editor believes that this financing is of profound significance: it marksThe Underrated Revolutionary Technology of In Situ Transdifferentiation Officially Moves from the Lab to Clinical Validation, while NEUREGEN has seized the commanding heights of a billion-dollar track with the world's first FDA IND-approved FIC drug for in-situ transdifferentiation in tumors.

From iPSC to In Situ Transdifferentiation: The Third Revolution in Cell Therapy is Approaching

To understand the value of NEUREGEN, it is necessary to first clarify why in-situ transdifferentiation is called the third revolution in cell therapy after stem cell transplantation and iPSC technology.

Traditional cell therapy is essentially "custom-made supercars outside the body," which involves extracting cells from patients, modifying and expanding them in the lab, and then reinfusing them. This process has three major pain points:

Extremely high cost：Million-dollar costs make it unaffordable for most patients
Long Cycle: It takes weeks from blood collection to reinfusion, and critically ill patients cannot wait.
Complex Process: Relying on a Class 10,000 cleanroom and cold chain, it is difficult to popularize.

In situ transdifferentiation achieves a breakthrough, akin to "on-site modification" within the patient's body: by precisely delivering reprogramming factors, cells in the diseased microenvironment are directly converted into functional cells, repairing tissues or eliminating diseased cells at the root.

Compared with iPSC technology, its advantages are prominent:

No Immune Rejection: Utilizing self-cell reprogramming to avoid rejection issues from exogenous cell transplantation
Higher Safety: Without going through the pluripotent stem cell stage, eliminating the risk of tumorigenicity
High conversion efficiency: Directly complete cell conversion in vivo, eliminating the loss from in vitro culture.

With these advantages, in-situ transdifferentiation is regarded as the most promising next-generation technology in regenerative medicine. Industry forecasts predict that this technology will enter a clinical boom period in the next 3-5 years, covering several major unmet clinical needs such as cancer and neurodegenerative diseases.

NEUREGEN's Triple Core Barriers: Why Is It Leading the Pack?

Many companies globally are laying out in situ transdifferentiation technology, but NEUREGEN is the first to obtain dual IND approvals from both China and the U.S., becoming the world's first company to advance in situ transdifferentiation therapy for tumors into clinical trials, relying on three insurmountable barriers at its core.

The First Barrier: A Globally Leading Original Technology Platform

NEUREGEN's core team consists of senior experts from multiple fields and owns an independent intellectual property rights platform for in-situ transdifferentiation technology. They have developed a multi-factor coordinated reprogramming system to achieve more efficient and precise cell identity conversion.

Based on this platform, the company has built a complete R&D system to support the rapid advancement of its pipeline. Its technology platform also won the Excellence Award in the finals of the 2024 Ministry of Science and Technology's National Disruptive Technology Innovation Competition, gaining recognition at the national level.

The Second Barrier: NRG-103, a Core Pipeline with Global First-in-Class Innovation

The core competitiveness of NEUREGEN lies in its key pipeline product, NRG-103 injection – a FIC innovative drug targeting high-grade gliomas.The World's First Tumor In-situ Transdifferentiation Therapy to Receive FDA Clinical Trial Approval。

High-grade gliomas are highly lethal, with a median survival of only 12-15 months for patients with glioblastoma. The 5-year survival rate is less than 5%, and the tumor recurrence rate is nearly 100%. The root cause lies in the insensitivity of glioma stem cells to conventional treatments.

NRG-103 adopts a triple mechanism of "oncolytic virus immune killing + immune enhancement + in-situ cell transdifferentiation," directly addressing the pain points:

1. A New Generation of Oncolytic Viruses Selectively Kills Tumor Cells

2. Release cytokines to activate the immune system and enhance anti-tumor response

3. Residual glioma stem cells and drug-resistant cells are redirected to transdifferentiate into non-proliferative cells, eliminating the root cause of recurrence.

Preclinical and IIT studies have preliminarily verified its safety and efficacy. The drug has now received CDE and FDA IND approval, entered Phase I clinical trials in China, and obtained FDA orphan drug designation, paving the way for global development.

The Third Barrier: A Highly Extensible Pipeline Layout

In addition to NRG-103, NEUREGEN has developed multiple pipelines in the fields of oncology, ophthalmology, and neurodegenerative diseases around its core technology platform. The "one platform, multiple products" model not only diversifies risks but also maximizes the value of the technology.

In the future, the in-situ transdifferentiation technology can also be extended to the treatment of diseases in other tissues and organs as well as the anti-aging field, providing long-term growth space for the company.

Behind the Collective Capital Bet: Dual Recognition of Industrial Logic and Investment Value

This round of financing attracted the participation of industrial capital, professional institutions, and existing shareholders, fully demonstrating the capital market's high recognition of NEUREGEN's technical strength and development prospects.

The lead investor, Wuhan Optics Valley Sci-Tech Innovation, has deep expertise in the biopharmaceutical field and empowers enterprises through an ecosystem of "mother fund + direct investment + industrial park." The co-investor, SoftBank Xinchuang, focuses on biomedicine and healthcare, possessing extensive industry resources that can support NEUREGEN in BD collaboration and global development.

Existing shareholders continue to increase their investments, demonstrating firm confidence in the company's development. The core logic of capital investment revolves around three key points:

1. Technical Scarcity: In-situ transdifferentiation is a cutting-edge technology, and NEUREGEN has established a significant leading advantage.

2. Large Market Space: The global market for high-grade gliomas alone is projected to reach $8.3 billion by 2034, with broader technological applications.

3. Strong team execution: Achieved the leap from technical validation to dual IND approval in China and the US within a short period, demonstrating outstanding R&D and clinical advancement capabilities.

Three Insights for Pharmaceutical Investors

NEUREGEN Financing Event Provides Three Key Insights for Pharmaceutical Investors:

First,Strategically Positioning in Revolutionary Frontier Technology Tracks. In-situ transdifferentiation is currently in its early stages, with disruptive potential already evident. It is expected to explode in the next 3-5 years, making now the optimal time for strategic positioning.

Second,Focus on Original Technology Platform CompaniesThere are many follow-up projects in the CGT track, but only platform enterprises with core independent intellectual property rights can stand out.

Third,Pay Attention to the Trends of Industrial CapitalIndustrial capital has a better understanding of industry trends and demands. Its investment decisions are based on in-depth research, and following its lead can help more accurately identify high-quality targets.

In Conclusion

In situ transdifferentiation technology ushers in a new era of treatment, with the potential to address the pain points of traditional cell therapy and bring hope of a cure for untreatable diseases.

As the leader in the field, the clinical progress of NRG-103 by NEUREGEN will become the market focus. If Phase I clinical trials yield positive results, it will validate the technical feasibility and increase the valuation of the field.

For investors, this is both an opportunity and a challenge. It requires continuous tracking of technological and clinical progress to share in the benefits of technological advancements while keeping risks under control.

We believe that in the future, more in-situ transdifferentiation innovative drugs will be approved, and NEUREGEN is expected to become a leading enterprise, writing a legendary chapter in China's biopharmaceutical innovation.

Scan the WeChat QR code to add.Medicine Space-TimeEditor

Please indicate: Name + Research Direction!